| Title: |
Efficacy and safety of Infliximab biosimilar, REMSIMA® in treatment of chronic plaque psoriasis. |
| Authors: |
Khalid, Nabigha; Batool, Saelah; Hanif, Sumera; Akbar, Talat; Asad, Faria; Nabi, Haroon |
| Source: |
Professional Medical Journal; May2025, Vol. 32 Issue 5, p583-588, 6p |
| Subject Terms: |
RESPIRATORY infections; EXPERIMENTAL design; DISEASE duration; PSORIASIS; PREVENTIVE medicine |
| Abstract: |
Objective: To assess the efficacy and safety of REMSIMA®, a biosimilar of infliximab in treatment of chronic plaque psoriasis. Study Design: Non-randomized Clinical Trial. Setting: Departments of Dermatology, GTTH and SIMS Lahore. Period: April, 2022 to July, 2023. Methods: A multi-centered study was conducted for which Informed consent was obtained for treatment with REMSIMA 120mg S/C given at 0,1,2,3,4,6,8,10 and 12 weeks. PASI was calculated at 0,4,8 and 12 weeks. Efficacy was measured as achievement of PASI-75 at 12 weeks. Relapse was checked on monthly regular follow ups till 24 weeks. Results: A total of 51 diagnosed patients of chronic plaque psoriasis were enrolled (1 was lost to followup, 1 had continuous fever, 1 discontinued due to elevated LFT's) 48 continued the treatment (72.9% males, 27.1% females) with age 18-59 years. Disease duration was >10 years in 20 patients and |
| : |
Copyright of Professional Medical Journal is the property of Professional Medical Journal and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |